Vanguard Group Inc. Grows Stock Position in NeoGenomics, Inc. (NASDAQ:NEO)

Vanguard Group Inc. boosted its position in NeoGenomics, Inc. (NASDAQ:NEO) by 1.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,239,887 shares of the medical research company’s stock after buying an additional 195,793 shares during the period. Vanguard Group Inc. owned approximately 0.11% of NeoGenomics worth $234,673,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. boosted its holdings in NeoGenomics by 5.4% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,134,651 shares of the medical research company’s stock valued at $16,736,000 after purchasing an additional 57,677 shares in the last quarter. FMR LLC boosted its stake in shares of NeoGenomics by 7.6% in the third quarter. FMR LLC now owns 13,255 shares of the medical research company’s stock valued at $196,000 after buying an additional 931 shares in the last quarter. BNP Paribas Financial Markets grew its holdings in NeoGenomics by 110.1% during the third quarter. BNP Paribas Financial Markets now owns 72,963 shares of the medical research company’s stock worth $1,076,000 after acquiring an additional 38,238 shares during the period. Verition Fund Management LLC purchased a new position in NeoGenomics in the third quarter worth $229,000. Finally, Paloma Partners Management Co acquired a new stake in NeoGenomics in the third quarter valued at $255,000. 98.50% of the stock is owned by institutional investors and hedge funds.

NeoGenomics Stock Up 0.7 %

NEO stock opened at $8.78 on Friday. The company has a 50 day moving average price of $11.39 and a two-hundred day moving average price of $14.11. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.91 and a current ratio of 1.98. The stock has a market capitalization of $1.13 billion, a P/E ratio of -14.16 and a beta of 1.28. NeoGenomics, Inc. has a one year low of $8.27 and a one year high of $19.12.

NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings data on Tuesday, February 18th. The medical research company reported ($0.02) EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.05). NeoGenomics had a negative net margin of 11.92% and a negative return on equity of 2.10%. The business had revenue of $172.00 million during the quarter, compared to analysts’ expectations of $173.40 million. As a group, sell-side analysts expect that NeoGenomics, Inc. will post -0.2 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. Piper Sandler lowered their price target on shares of NeoGenomics from $21.00 to $18.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 26th. The Goldman Sachs Group dropped their target price on shares of NeoGenomics from $20.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, January 28th. Bank of America lowered their price target on NeoGenomics from $19.00 to $16.00 and set a “neutral” rating on the stock in a report on Wednesday, February 19th. Needham & Company LLC dropped their price objective on NeoGenomics from $19.00 to $18.00 and set a “buy” rating for the company in a research note on Wednesday, February 19th. Finally, Benchmark downgraded NeoGenomics from a “buy” rating to a “hold” rating in a research report on Monday, January 13th. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, NeoGenomics presently has a consensus rating of “Moderate Buy” and an average price target of $19.60.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.